Liquid Biopsy Market to Reach US$ 25.19 Billion by 2033, Driven by Rising Cancer Incidence and Precision Medicine Demand

According to DataM Intelligence, the Global Liquid Biopsy Market reached US$ 9.07 billion in 2024 and is projected to rise to US$ 25.19 billion by 2033, growing at a robust CAGR of 10.7% during 2025-2033. This growth is driven by increasing global cancer prevalence, advances in genomic research, and growing adoption of non-invasive diagnostic tools.

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/liquid-biospy-market?utm_source=OpenPR&utm_campaign=Onkar

Liquid biopsy-a minimally invasive test-detects biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes in body fluids. It offers key advantages for early cancer detection, monitoring therapy response, and tracking tumor progression. North America dominates the market due to strong healthcare infrastructure, FDA-backed innovation, and high investment in precision oncology.

Key Highlights from the Report

➤ Global liquid biopsy market to grow from US$ 9.07 billion in 2024 to US$ 25.19 billion by 2033 at a CAGR of 10.7%.
➤ Kits and reagents segment leads the market owing to continuous product launches and research demand.
➤ North America dominates the market with strong regulatory support and advanced precision medicine programs.
➤ Liquid biopsy applications expanding beyond oncology into prenatal testing and organ transplantation.
➤ Technological upgrades like Guardant Health's 739-gene panel enhance biomarker detection sensitivity.
➤ AI-driven platforms (e.g., SOPHiA GENETICS) enable real-time genomic analysis for personalized healthcare.

Market Segmentation

The global liquid biopsy market is segmented by product type, circulating biomarker, application, technology, end-user, and region.

Product Type: Kits and Reagents Lead Segment Growth
The kits and reagents segment holds the largest market share due to their integral role in extracting and analyzing biological samples such as ctDNA and cfDNA. Companies like Twist Bioscience and QIAGEN are expanding product lines to support clinical and research applications. QIAGEN's upgraded sample solutions (October 2024) and Twist Bioscience's cfDNA Library Prep Kit (February 2024) illustrate ongoing innovation fueling the sector's expansion.

Application: Oncology Dominates with Rising Use in Precision Cancer Diagnostics

Liquid biopsy tests are primarily used in oncology for cancer detection and therapeutic monitoring. They help clinicians assess tumor heterogeneity, track minimal residual disease, and optimize targeted drug selection. The expanding role of RNA-based testing, as seen in GeneCentric Therapeutics' EXpressCTSM platform, highlights diversification beyond classic DNA analysis.

Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/liquid-biospy-market?utm_source=OpenPR&utm_campaign=Onkar

Regional Insights

North America: Largest and Most Advanced Market
North America remains the dominant region due to widespread adoption of non-invasive diagnostics, a high cancer prevalence, and FDA support for biomarker-based testing. Guardant Health's 2024 launch of its enhanced Guardant360 test-analyzing 739 genes-demonstrates innovation leadership in detecting complex cancer mutations. Increasing precision oncology investments and research collaborations also support market growth.

Europe and Asia-Pacific: Emerging Hubs for Innovation
Europe benefits from growing demand for early diagnostic tools and expanding biomarker research collaborations. Meanwhile, Asia-Pacific is emerging as a strong growth region driven by rising cancer incidence, improving healthcare infrastructure, and regional collaborations promoting accessible genomic testing in countries like Japan, South Korea, and India.

Market Dynamics

Market Drivers

The continuous rise in global cancer cases fuels the need for early, precise, and non-invasive diagnostic approaches. Advances in genomics and biomarker studies allow for real-time monitoring of cancer dynamics, strengthening the clinical value of liquid biopsy in treatment planning and disease management.

Market Restraints

The lack of standardization in testing protocols remains a key restraint. Inconsistent sample processing methods, complex validation requirements, and high regulatory hurdles-particularly from the FDA and EMA-slow mass adoption and product approvals.

Market Opportunities

Integration of AI and machine learning in data interpretation, expanding applications in prenatal diagnostics, and commercialization of advanced biomarker test kits create lucrative opportunities. Strategic collaborations between biotechnology and diagnostic firms are set to accelerate adoption in both clinical and research segments.

Purchase This Exclusive Report at Just USD 4442 Only: https://www.datamintelligence.com/buy-now-page?report=liquid-biospy-market?utm_source=OpenPR&utm_campaign=Onkar

Reasons to Buy the Report

✔ In-depth market forecasts and growth insights through 2033.
✔ Comprehensive analysis of product innovations and technological advancements.
✔ Regional overview of market dynamics, investment patterns, and regulatory environment.
✔ Profiles of leading diagnostic and biotechnology companies driving innovation.
✔ Evaluation of AI integration and its impact on next-gen liquid biopsy platforms.

Frequently Asked Questions (FAQs)

◆ How big is the global liquid biopsy market in 2024?
◆ What is the projected market CAGR during 2025-2033?
◆ Which region dominates the global liquid biopsy market?
◆ Who are the key players revolutionizing the liquid biopsy landscape?
◆ What are the major growth factors influencing market expansion?

Company Insights
Exosome Sciences Inc.

Illumina, Inc.

Guardant Health, Inc.

Thermo Fisher Scientific Inc.

NeoGenomics Laboratories

QIAGEN

BioChain Institute Inc.

Sysmex Europe SE

Eurofins Genomics

Goffin Molecular Technologies

Recent Developments

February 2025: SOPHiA GENETICS achieved a major milestone, with 37 global institutions adopting its MSK-ACCESS and MSK-IMPACT AI-powered platforms, revolutionizing cancer testing and data-driven precision medicine.

October 2024: GeneCentric Therapeutics launched the EXpressCTSM liquid biopsy platform, expanding RNA-based diagnostic applications to include cfDNA in blood and urine assays.

Conclusion
The Global Liquid Biopsy Market is at the forefront of revolutionizing cancer diagnostics with its precision, speed, and non-invasive benefits. While North America continues to command leadership due to technological innovation, emerging markets across Asia-Pacific and Europe are accelerating adoption through research collaboration and improved genomic infrastructure. As regulatory clarity improves and AI-driven testing becomes mainstream, liquid biopsy is poised to become an essential tool for early cancer detection and personalized healthcare by 2033.

Contact Us

Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com

About Us

DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.

This release was published on openPR.